American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
2.
American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
3.
Baughman FA. Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder (Letter). Pediatrics. 2000;106:1239-1240.
4.
Practice parameter for the use of stimulant medication in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:2(supplement):26S-49S.
5.
McGuiness D. Attention deficit disorder: the emperor’s clothes, animal “pharm,” and other fiction. In: Fisher S, Greenburg RP, eds. The Limits of Biological Treatments for Psychological Distress. Hillsdale, NJ: Lawrence Erbaum Associates; 1989:151-187.
6.
Furman RA. Attention deficit/hyperactivity disorder: an alternative viewpoint. J Int Child Adolesc Psychiatry. 2002;2:125-144.
7.
Weinberg WA, Brumback WA. The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes. J Child Neurol. 1992;7:431-435.
8.
El-Sayed E, Larsson JO, Persson HE, et al.“Maturational lag” hypothesis of attention deficit/hyperactivity disorder: an update. Acta Pediatr. 2003;92:776-784.
9.
Carey WB. Is attention deficit hyperactivity a valid disorder? Invited presentation to the NIH Consensus Development Conference on ADHD, November 16-18, 1998, National Institutes of Health, Bethesda, MD.
10.
Coles G. The Learning Mystique. New York: Pantheon Books; 1987.
11.
Drug Enforcement Administration, Office of Public Affairs. Methylphenidate and Amphetamine Yearly Production Quota (1980-2000). Washington, DC: Department of Justice; 2001.
12.
Drug Enforcement Administration, Office of Diversion Control. Methylphenidate. A background paper. Washington, DC, Department of Justice, October 1995.
13.
Furman RA. Methylphenidate and “ADHD” in Europe and the United States. Child Analysis. 1996;7:132-145.
14.
Rappaport JL, Buchsbaum MS, Weingartner H, et al.Dextroamphetamine. Cognitive and behavioral effects in normal prepubertal boys. Science. 1978;199:560-563.
15.
Rappaport JL, Buchsbaum MS, Weingartner H, et al.Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and men. Arch Gen Psychiatry. 1980;37:933-943.
16.
Bernstein GA, Carroll ME, Crosby RD, et al.Caffeine effects on learning, performance and anxiety in normal school-age children. J Am Acad Child Adolesc Psychiatry. 1994;33:407-415.
17.
Zito JM, Safer DJ, dosReis S, et al.Trends in the prescribing of psychotropic medication to preschoolers. JAMA. 2000;283:1025-1030.
18.
Diller L. Lessons from three year olds. Dev Behav Pediatr. 2002;23:S10-S12.
19.
Fraser KM. Too young for attention deficit disorder? Views from preschool. Dev Behav Pediatr. 2002;23:S46-S50.
20.
Pozzi ME. Ritalin for whom? J Child Psychotherapy. 2000;26:25-43.
21.
Jacobvitz D, Sroufe LA. The early care-giver child relationship and attention deficit disorder with hyperactivity in kindergarten: a prospective study. Child Dev. 1987;58:1488-1495.
